TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hua Medicine ( (HK:2552) ) has issued an update.
Hua Medicine has announced an updated list of its board of directors effective November 27, 2025. The announcement details the roles and committee memberships of each director, highlighting the strategic leadership structure within the company. This update may influence the company’s governance and strategic direction, impacting stakeholders and potentially enhancing its position in the pharmaceutical industry.
The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.
More about Hua Medicine
Hua Medicine is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. It focuses on developing innovative therapies and solutions, particularly in the area of diabetes treatment.
Average Trading Volume: 6,785,616
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.15B
See more insights into 2552 stock on TipRanks’ Stock Analysis page.